Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis

BACKGROUND: Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcomes of RTX in adults with FSGS and MCD. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansrivijit, Panupong, Cheungpasitporn, Wisit, Thongprayoon, Charat, Ghahramani, Nasrollah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160971/
https://www.ncbi.nlm.nih.gov/pubmed/32293308
http://dx.doi.org/10.1186/s12882-020-01797-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160971/
https://www.ncbi.nlm.nih.gov/pubmed/32293308
http://dx.doi.org/10.1186/s12882-020-01797-7

Ejemplares similares